F.D.A. Advisers Meets on Merck ’s Covid Pill

If an expert committee votes to recommend it, the drug, molnupiravir, could be authorized within days for patients at high risk of severe illness.

Source: NYT Health - November 30, 2021 Category: Consumer Health News Authors: Rebecca Robbins and Carl Zimmer Tags: Molnupiravir (Drug) Coronavirus (2019-nCoV) Merck & Company Inc Food and Drug Administration Coronavirus Omicron Variant Vaccination and Immunization Source Type: news